These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiviral therapeutics for the treatment of Ebola virus infection. Cardile AP; Downey LG; Wiseman PD; Warren TK; Bavari S Curr Opin Pharmacol; 2016 Oct; 30():138-143. PubMed ID: 27639220 [TBL] [Abstract][Full Text] [Related]
4. A dose of reality. Cohen J; Kupferschmidt K Science; 2014 Nov; 346(6212):908-11. PubMed ID: 25414285 [No Abstract] [Full Text] [Related]
5. A US Food and Drug Administration perspective on evaluating medical products for Ebola. Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565 [No Abstract] [Full Text] [Related]
6. Ebola drug trial is terminated after fall in number of new cases. Gulland A BMJ; 2015 Feb; 350():h664. PubMed ID: 25656547 [No Abstract] [Full Text] [Related]
7. Statistical considerations for a trial of Ebola virus disease therapeutics. Proschan MA; Dodd LE; Price D Clin Trials; 2016 Feb; 13(1):39-48. PubMed ID: 26768567 [TBL] [Abstract][Full Text] [Related]
8. Tough challenges for testing Ebola therapeutics. Fleck F Bull World Health Organ; 2015 Feb; 93(2):70-1. PubMed ID: 25883398 [TBL] [Abstract][Full Text] [Related]
9. Rethinking the development of Ebola treatments. Gupta R Lancet Glob Health; 2014 Oct; 2(10):e563-4. PubMed ID: 25304627 [No Abstract] [Full Text] [Related]
10. A viewpoint on European Medicines Agency experience with investigational medicinal products for Ebola. Cavaleri M; Thomson A; Salmonson T; Hemmings RJ Clin Trials; 2016 Feb; 13(1):101-4. PubMed ID: 26768561 [No Abstract] [Full Text] [Related]
11. Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use. Hantel A; Olopade CO Ann Intern Med; 2015 Jan; 162(2):141-2. PubMed ID: 25322080 [No Abstract] [Full Text] [Related]
13. WHO gives go ahead for experimental treatments to be used in Ebola outbreak. Sayburn A BMJ; 2014 Aug; 349():g5161. PubMed ID: 25122051 [No Abstract] [Full Text] [Related]
14. Prioritising Healthcare Workers for Ebola Treatment: Treating Those at Greatest Risk to Confer Greatest Benefit. Satalkar P; Elger BE; Shaw DM Dev World Bioeth; 2015 Aug; 15(2):59-67. PubMed ID: 25655050 [TBL] [Abstract][Full Text] [Related]
15. Infectious diseases. Debate erupts on 'repurposed' drugs for Ebola. Enserink M Science; 2014 Aug; 345(6198):718-9. PubMed ID: 25124404 [No Abstract] [Full Text] [Related]
16. The early clinical development of Ebola virus treatments. Bradfute SB Expert Opin Investig Drugs; 2017 Jan; 26(1):1-4. PubMed ID: 27838928 [No Abstract] [Full Text] [Related]
17. Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies. Zhang T; Zhai M; Ji J; Zhang J; Tian Y; Liu X Bioorg Med Chem Lett; 2017 Jun; 27(11):2364-2368. PubMed ID: 28462833 [TBL] [Abstract][Full Text] [Related]
18. Favipiravir for children with Ebola. Bouazza N; Treluyer JM; Foissac F; Mentré F; Taburet AM; Guedj J; Anglaret X; de Lamballerie X; Keïta S; Malvy D; Frange P Lancet; 2015 Feb; 385(9968):603-604. PubMed ID: 25706078 [No Abstract] [Full Text] [Related]
19. FDA allows second experimental drug to be tested in Ebola patients. McCarthy M BMJ; 2014 Aug; 349():g5103. PubMed ID: 25113141 [No Abstract] [Full Text] [Related]
20. Ethical allocation of drugs and vaccines in the West African ebola epidemic. Gostin LO Milbank Q; 2014 Dec; 92(4):662-6. PubMed ID: 25492601 [No Abstract] [Full Text] [Related] [Next] [New Search]